tiprankstipranks
Advertisement
Advertisement
Psychedelic: Clearmind completes Part A dosing for Phase I/II CMND-100 trial
PremiumThe FlyPsychedelic: Clearmind completes Part A dosing for Phase I/II CMND-100 trial
23d ago
Clearmind Medicine granted U.S. patent for Binge Behavior Regulators
Premium
The Fly
Clearmind Medicine granted U.S. patent for Binge Behavior Regulators
23d ago
Clearmind Medicine completes dosing for four cohorts of CMND-100 trial
Premium
The Fly
Clearmind Medicine completes dosing for four cohorts of CMND-100 trial
25d ago
Psychedelic: Enveric, NRx, Bright Minds report quarterly earnings
PremiumThe FlyPsychedelic: Enveric, NRx, Bright Minds report quarterly earnings
2M ago
Clearmind Medicine Inc trading halted, news pending
Premium
The Fly
Clearmind Medicine Inc trading halted, news pending
2M ago
Clearmind Medicine announces 1-for-10 reverse share split
Premium
The Fly
Clearmind Medicine announces 1-for-10 reverse share split
2M ago
Clearmind Medicine files to sell 22.63M common shares for holders
PremiumThe FlyClearmind Medicine files to sell 22.63M common shares for holders
2M ago
Psychedelic: FDA awards Compass Pathways priority review voucher
Premium
The Fly
Psychedelic: FDA awards Compass Pathways priority review voucher
2M ago
Clearmind announces evaluation of CMND-100 for breakthrough therapy designation
Premium
The Fly
Clearmind announces evaluation of CMND-100 for breakthrough therapy designation
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100